Key points are not available for this paper at this time.
To the editor: Ibrutinib, approved by the US Food and Drug Administration (FDA), is an inhibitor of Bruton tyrosine kinase (BTK).11⇓2⇓3⇓4-55 Ibrutinib use is associated with atrial fibrillation (AF), with an incidence of 5% to 6% after 18 months on therapy44⇓5-[6
Lampson et al. (Tue,) studied this question.